Korro Bio, Inc. (KRRO) Stock

Korro Bio, Inc. (KRRO) is a Healthcare stock trading at $13.01 (as of 2026-06-18), with a market capitalization of $193.41M and a trailing P/E of -1.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Korro Bio, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing genetic medicines that use RNA editing. It works on treatments for rare and highly prevalent diseases.

Valuation — source: SEC EDGAR (first-party)
Price$13.01
Market Cap$193.41M
P/E Ratio-1.1
EV / EBITDA-1.1
Price / Book1.57
Price / Sales48.76
DCF Value (model)$-91.83
DCF Upside vs Price-805.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$6.39M
Net Margin-1834.5%
Return on Equity-94.9%
Current Ratio8.13
Revenue Growth (YoY)181.5%
EPS Growth (YoY)33.2%
FCF Growth (YoY)1.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.66 (distress)
Valuation vs Sector & Industry
Stock P/E-1.1
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-105.3%
vs Industry-106.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderPoint72 Asset Management, L.P. ($25.48M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORam Aiyar
Employees112
CountryUS
IPO Date2019-10-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Adicet Bio, Inc. (ACET)
  • Nasus Pharma Ltd. (NSRX)
  • Acrivon Therapeutics, Inc. Common Stock (ACRV)
  • Pliant Therapeutics, Inc. (PLRX)
  • InflaRx N.V. (IFRX)
  • CEL-SCI Corporation (CVM)
  • CervoMed Inc. (CRVO)
  • Pyxis Oncology, Inc. (PYXS)
KRRO earnings history · KRRO institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.